Lumen Biosciences Brian Finrow breaks down Chinas biotech playbook and explores ways the U.S. can adapt it for its own continued success.

Part one of a two-part series on FDA Commissioner Martin Makary, M.D.s comments at the Gailen Forum in New York City on October 30, 2025.

Women leaders are driving success in life sciences but remain underrepresented and undervalued. That needs to change, writes ...

Pay close attention to contract language regarding royalties, including when and where patents expire, or pay the price, ...

Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write ...

The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...

Since the start of his second term, President Trump has shown a clear commitment to improving access to medicines for American patients. In late September 2025, his Administration reaffirmed this ...

Roger Cone, Ph.D., a professor at the University of Michigan and the founder and chair of the scientific advisory board at Courage Therapeutics, has been thinking about the biological mechanics of ...

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

The GLP-1 drug market is booming, fueled by their success in treating diabetes and obesity. Yet, this growth has unleashed a torrent of litigation — patent disputes, regulatory battles, and clashes ...